We evaluated the incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease. We also assessed the predictive role of bone turnover markers determined at baseline.
Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline.
Dipartimento di Scienze Cliniche e Biologiche, Università di Torino, Clinica Medica, Oncologia Medica e Urologia, Azienda Ospedaliera San Luigi, Orbassano, Italy.
